3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
275
Gynecologic
4
Other
3
Thoracic
1
Sarcoma
1
Other neoplasm
1
Lymphoid
1
Head & Neck
1
Endocrine
1
Conditions
Neoplasm Metastasis
2
Multiple Endocrine Neoplasia Type 1
2
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Sarcoma
1
Pheochromocytoma
1
Optic Nerve Glioma
1
Oligodendroglioma
1
Neuroendocrine Tumors
1
Mesothelioma, Malignant
1
Medulloblastoma
1
Liver Neoplasms
1
Hyperglycemia
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Glioma, Subependymal
1
Glioma
1
Glioblastoma
1
Familial ependymoma
1
Ependymoma
1
Central Nervous System Neoplasms
1
Carcinoma, Medullary
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Brain Neoplasms
1
Astrocytoma
1
Adrenocortical Carcinoma
1
Adenocarcinoma, Follicular
1
Interventions
selpercatinib
3
Fulvestrant
3
Fluorodeoxyglucose F18
3
ribociclib
2
Trastuzumab
2
Magnetic Resonance Spectroscopy
2
Letrozole
2
Cyclophosphamide
2
Alpelisib
2
vandetanib
1
tivozanib
1
tipifarnib
1
temsirolimus
1
romidepsin
1
pembrolizumab
1
gadoteridol
1
gadoterate meglumine
1
gadolinium ethoxybenzyl DTPA
1
gadodiamide
1
gadobutrol
1
gadobenic acid
1
fludarabine phosphate
1
fludarabine
1
exemestane
1
entrectinib
1
entinostat
1
avelumab
1
atezolizumab
1
alectinib
1
aldesleukin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
Tamoxifen
×
Endocrine
×
Clear all
NCT04300790
2025-07-29
METALLICA
MedSIR
Phase 2
Completed
69 enrolled